The latest selling price of Ixabepilone at home and abroad in 2025

As of2025, Ixabepilone () has not yet been officially launched in mainland China, so there is no official price and medical insurance reimbursement information in the domestic pharmacy or hospital system. Currently, there is no domestic generic version or import agent of this drug, and it can only be obtained through overseas specialty drug channels. According to market data in the United States and Europe, the original version of ixabepilone is produced by Bristol Myers Squibb and sold under the trade name Ixempra. Its specifications include 15 mg and 45 mg freeze-dried powder for injection.

In overseas markets, the price of ixabepilone is relatively expensive. Taking the United States as an example, A 15mg package costs about US$2,000, and a 45mg package costs about US$6,000, which is equivalent to about 15,000 to 45,000 yuan per tube. The price will fluctuate slightly depending on different regions and pharmacy channels. Pricing in some European countries is slightly lower, but overall it is still a high-cost chemotherapy drug. Because ixabepilone is a special anti-cancer drug, its production process is complex and storage requirements are high. In addition, there are no generic drugs on the market, resulting in long-term high prices.

Although China has not introduced it yet, some cross-border medical platforms or global pharmacies provide drug purchase services, and original drugs can be obtained from the United States and other places. It is worth noting that there are currently no generic drugs approved by Laos or other countries, so patients should confirm the legality of the drug source and the authenticity of the drug when purchasing.

In terms of drug and medical insurance coverage, the FDA in the United Stateshas approved ixabepilone mainly for chemotherapy-resistant metastatic breast cancer, and some insurance plans can partially reimburse it; in Europe, according to different national policies, patients can apply for drug subsidies through specialized cancer centers. China does not yet have a medical insurance code, nor is it included in the national drug catalog. Therefore, if patients want to use the drug, they usually need to import it at their own expense or participate in international clinical projects.

Judging from future trends, with the advancement of personalized treatment of breast cancer in China, ixabepilone is expected to become one of the important choices for drug-resistant patients. If a domestically produced generic version is launched after its patent expires, the price is expected to drop significantly, and there is a chance it will be included in the medical insurance catalog, thereby improving patient accessibility.

Reference materials:https://www.drugs.com/mtm/ixabepilone.html